Onconova (NASDAQ: ONTX) was downgraded by Zacks.com from a “buy” rating to a “hold” ranking in a research note provided to investors on Thursday, Zacks.com reports.
According to Zacks, “Onconova Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It concentrates on uncovering and establishing small molecule drug candidates to deal with cancer cells. The Company‘s products under different stages of growth include Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 and Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania. “
A number of various other equities research experts also just recently commented on the company. Noble Financial editioned a “buy” ranking and also provided a $11.00 price goal on shares of Onconova Therapeutics in a record on Thursday, September 23rd. Guggenheim dropped their price target on Onconova Therapeutics from $29.00 to $12.00 and also set a “buy” score on the stock in a research note on Tuesday, September 28th.
NASDAQ: ONTX opened at $2.25 on Thursday. Onconova Therapeutics has a twelve month low of $2.22 as well as a twelve month high of $28.95. Business has a 50 day moving typical cost of $2.90 and also a two-hundred day moving typical price of $4.16. The company has a market cap of $46.76 million, a P/E proportion of -1.82 as well as a beta of 1.67.
Onconova Therapeutics (NASDAQ: ONTX) last launched its quarterly incomes outcomes on Thursday, November 11th. The biopharmaceutical business reported ($ 0.22) revenues per share for the quarter, covering analysts’ consensus estimates of ($ 0.33) by $0.11. Onconova Therapeutics had a negative return on equity of 59.78% as well as a negative net margin of 8,294.27%. The company had profits of $0.06 million during the quarter, contrasted to the agreement price quote of $0.06 million. Throughout the exact same quarter in the prior year, the company posted ($ 0.45) EPS. As a group, research experts forecast that Onconova Therapeutics will certainly post -1.18 EPS for the existing year.
A number of hedge funds have lately bought and sold shares of ONTX. GSA Capital Allies LLP got a new setting in Onconova Therapeutics during the 3rd quarter worth $922,000. Hudson Bay Resources Monitoring LP acquired a brand-new setting in shares of Onconova Therapeutics in the 3rd quarter worth $635,000. Pura Vida Investments LLC purchased a brand-new position in shares of Onconova Therapeutics in the third quarter worth $575,000. CVI Holdings LLC bought a brand-new placement in shares of Onconova Therapeutics in the 3rd quarter worth $493,000. Ultimately, Dimensional Fund Advisors LP got a brand-new position in shares of Onconova Therapeutics in the 2nd quarter worth $509,000. Hedge funds as well as various other institutional investors own 13.36% of the business’s stock.
About Onconova Therapeutics
Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical firm, which participates in the identification as well as development of oncology therapeutics. It focuses on discovering and also developing small molecule medicine candidates to deal with cancer. The firm was founded by Ramesh Kumar and E. Premkumar Reddy on December 22, 1998 and is headquartered in Newtown, PA
. Get a totally free duplicate of the Zacks research record on Onconova Therapeutics (ONTX).
For more information regarding research offerings from Zacks Investment Research, go to Zacks.com.
This instantaneous news alert was created by narrative science technology and also economic information from Market in order to offer viewers with the fastest and also most accurate reporting. This story was assessed by Market’s content group before publication.
SHOULD YOU SPEND $1,000 IN ONCONOVA THERAPEUTICS TODAY?
Before you think about Onconova Therapeutics, you’ll wish to hear this.
Market keeps track of Wall Street’s top-rated as well as ideal carrying out research experts and also the stocks they suggest to their customers daily. Market has actually recognized the 5 stocks that cover experts are silently murmuring to their clients to purchase now prior to the broader market catches on … as well as Onconova Therapeutics had not been on the listing.
While Onconova Therapeutics currently has a “Buy” score amongst analysts, premier analysts think these five stocks are better gets.
